Custom Powders BV

Contract Manufacturing in the German Pharmaceutical Industry

Contract pharmaceutical manufacturing in Germany has grown significantly over recent decades as global pharmaceutical companies seek to optimise their manufacturing footprints and reduce capital expenditure on production capacity. German CMOs benefit from the country's engineering expertise, well-trained workforce, strong regulatory standing and proximity to European clients. The German CMO market serves a diverse client base: established pharmaceutical companies outsourcing non-core production, generic manufacturers seeking additional capacity, biotech startups without their own manufacturing facilities, and international companies seeking a European manufacturing base with GMP certification recognised by the EMA and FDA. The services offered by German CMOs span the full development-to-commercial lifecycle, from formulation and process development in the lab through pilot-scale production and technology transfer to full commercial manufacturing and distribution. Germany's high GMP standards mean that products manufactured by German CMOs are accepted in regulatory submissions worldwide.

GMP Requirements and State Inspections for German CMOs

All pharmaceutical contract manufacturers in Germany must operate in compliance with EU GMP guidelines (EudraLex Volume 4) as a condition of holding a manufacturing authorisation under Section 13 of the AMG. GMP covers every aspect of pharmaceutical manufacturing: facility design and qualification, equipment qualification and calibration, cleaning validation, process validation, personnel training and hygiene, starting material and finished product testing, batch record documentation, stability studies, and management of deviations, out-of-specification results and change controls. GMP compliance is verified through inspections conducted by the pharmaceutical supervisory authority of the relevant German federal state (Landesbehörde). Inspections may be routine, announced or unannounced. Inspection findings are classified by severity (critical, major, minor) and manufacturers must respond with corrective and preventive action plans (CAPAs). GMP inspection results are entered into the EudraGMDP database. Foreign regulatory authorities such as the FDA, PMDA (Japan) and TGA (Australia) also conduct inspections of German CMOs that supply their markets.

Sterile Manufacturing and Specialised CMO Capabilities in Germany

Germany has a particularly strong track record in sterile pharmaceutical manufacturing, a technically demanding and heavily regulated segment of the CMO market. Sterile manufacturing encompasses injectable products (vials, ampoules, pre-filled syringes, cartridges), ophthalmic preparations (eye drops, eye ointments), inhalation solutions and infusion bags. These products must be manufactured in controlled cleanroom environments classified according to EU GMP Annex 1, which underwent a major revision in 2022 introducing the concept of contamination control strategy (CCS). Germany's engineering and cleanroom construction companies are world leaders in pharmaceutical facility design, making the country an attractive location for state-of-the-art sterile manufacturing investments. Beyond sterile manufacturing, German CMOs offer specialised capabilities in highly potent APIs (HPAPIs) and cytotoxic products requiring containment, modified-release oral dosage forms, transdermal drug delivery systems, biologics fill-and-finish, and clinical trial material manufacturing (CTMS).

Specialisations and the Growing Contract Manufacturing Market

The global market for pharmaceutical contract manufacturing is growing at approximately eight percent annually and is projected to exceed 300 billion US dollars by 2030. Growth drivers include the outsourcing strategy of large pharmaceutical companies, the growth of small biotech startups without their own production capacities and increasing demand for biologics and Advanced Therapy Medicinal Products (ATMPs). German contract manufacturers have established themselves in several niches: sterile manufacturing (injection solutions, lyophilisates) requires ultra-clean cleanrooms to ISO classifications; HPAPI containment (highly potent active pharmaceutical ingredients) requires specialist fume cupboards and personal protection measures; biologics CMOs require bioreactors and cell culture technology. CDMOs (Contract Development and Manufacturing Organizations) additionally offer formulation development and clinical trial materials. Important players in the German CMO market include Rentschler, Boehringer Ingelheim Biopharmaceuticals, Siegfried and Corden Pharma.